Search
Sotorasib
go.drugbank.com/drugs/DB15569ApprovedInvestigational[A187547] Sotorasib was granted FDA approval on May 28, 2021,[L34288] followed by the European Commission's approval on January 6, 2022.[L56070]
Levodopa
go.drugbank.com/drugs/DB01235ApprovedInvestigationalThe first developed drug product that was approved by the FDA was a levodopa and carbidopa combined product called Sinemet that was approved on May 2, 1975[A177781,L6133].
Chlortetracycline
go.drugbank.com/drugs/DB09093ApprovedVet approvedWithdrawnChlortetracycline is a tetracycline antibiotic, and historically the first member of this class to be identified. It was discovered in 1945 by the scientist, Benjamin Minge Duggar, working at Lederle Laboratories under the supervision of...
Alpelisib
go.drugbank.com/drugs/DB12015ApprovedInvestigationalAlpelisib was granted FDA approval on 24 May 2019. … [L6652] In April 2022, the FDA granted the use of alpelisib in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS) in adults and children who require systemic therapy.[L41384]
Ipratropium
go.drugbank.com/drugs/DB00332ApprovedInvestigational[A176957] Ipratropium as a therapeutic agent was developed by Boehringer Ingelheim and its first monotherapy product was FDA approved in 1986, while the combination product of ipratropium and [albuterol
Normethadone
go.drugbank.com/drugs/DB11609ApprovedIllicitNormethadone is used as an opioid antitussive in combination with DB11610. It is marketed in Canada by Valeant under the tradename Cophylac.
Bedaquiline
go.drugbank.com/drugs/DB08903ApprovedInvestigational[A261856,A261861] It is the first drug that was approved in the last 40 years by the FDA for TB unresponsive to current treatments on the market. … [A261861] Bedaquiline was approved by the FDA on December 28, 2012, to treat pulmonary MDR-TB, following favorable results in multiple pre-clinical and clinical studies.
Melphalan flufenamide
go.drugbank.com/drugs/DB16627ApprovedWithdrawn[A230143,L32173] Melphalan flufenamide was granted FDA approval on 26 February 2021.[L32173].
Inavolisib
go.drugbank.com/drugs/DB15275ApprovedInvestigationalInavolisib is an inhibitor of PI3Kα that was approved by the FDA in October 2024 for the treatment of certain patients with advanced breast cancers.
Nomifensine
go.drugbank.com/drugs/DB04821ApprovedWithdrawnFDA published a notice of its determination that Merital capsules were removed from the market for safety reasons (see the Federal Register of June 17, 1986 (51 FR 21981)). … Approval of the NDA for Merital capsules was withdrawn on March 20, 1992 (see the Federal Register of March 20, 1992 (57 FR 9729)). Also withdrawn from the Canadian and UK markets.